Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines

M. Elvira P. Correa, Karis Kin Fong Cheng, Karen Chiang, Abhishek Kandwal, Charles L. Loprinzi, Takehiko Mori, Carin Potting, Tanya Rouleau, Juan J. Toro, Vinisha Ranna, Anusha Vaddi, Douglas E. Peterson, Paolo Bossi, Rajesh V. Lalla, Sharon Elad

Research output: Contribution to journalArticle

Abstract

Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.

Original languageEnglish
JournalSupportive Care in Cancer
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Stomatitis
Cryotherapy
Practice Guidelines
Guidelines
Neoplasms
Melphalan
Hematopoietic Stem Cells
Fluorouracil
Databases
Transplants
Mucositis
Medical Oncology
Triage
PubMed
Therapeutics
Drug Therapy

Keywords

  • Cancer
  • Cryotherapy
  • Guidelines
  • Oral mucositis

ASJC Scopus subject areas

  • Oncology

Cite this

Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. / Correa, M. Elvira P.; Cheng, Karis Kin Fong; Chiang, Karen; Kandwal, Abhishek; Loprinzi, Charles L.; Mori, Takehiko; Potting, Carin; Rouleau, Tanya; Toro, Juan J.; Ranna, Vinisha; Vaddi, Anusha; Peterson, Douglas E.; Bossi, Paolo; Lalla, Rajesh V.; Elad, Sharon.

In: Supportive Care in Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Correa, MEP, Cheng, KKF, Chiang, K, Kandwal, A, Loprinzi, CL, Mori, T, Potting, C, Rouleau, T, Toro, JJ, Ranna, V, Vaddi, A, Peterson, DE, Bossi, P, Lalla, RV & Elad, S 2019, 'Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines', Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-05217-x
Correa, M. Elvira P. ; Cheng, Karis Kin Fong ; Chiang, Karen ; Kandwal, Abhishek ; Loprinzi, Charles L. ; Mori, Takehiko ; Potting, Carin ; Rouleau, Tanya ; Toro, Juan J. ; Ranna, Vinisha ; Vaddi, Anusha ; Peterson, Douglas E. ; Bossi, Paolo ; Lalla, Rajesh V. ; Elad, Sharon. / Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. In: Supportive Care in Cancer. 2019.
@article{150e6aab314a49ac90f92d491898f057,
title = "Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines",
abstract = "Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.",
keywords = "Cancer, Cryotherapy, Guidelines, Oral mucositis",
author = "Correa, {M. Elvira P.} and Cheng, {Karis Kin Fong} and Karen Chiang and Abhishek Kandwal and Loprinzi, {Charles L.} and Takehiko Mori and Carin Potting and Tanya Rouleau and Toro, {Juan J.} and Vinisha Ranna and Anusha Vaddi and Peterson, {Douglas E.} and Paolo Bossi and Lalla, {Rajesh V.} and Sharon Elad",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00520-019-05217-x",
language = "English",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines

AU - Correa, M. Elvira P.

AU - Cheng, Karis Kin Fong

AU - Chiang, Karen

AU - Kandwal, Abhishek

AU - Loprinzi, Charles L.

AU - Mori, Takehiko

AU - Potting, Carin

AU - Rouleau, Tanya

AU - Toro, Juan J.

AU - Ranna, Vinisha

AU - Vaddi, Anusha

AU - Peterson, Douglas E.

AU - Bossi, Paolo

AU - Lalla, Rajesh V.

AU - Elad, Sharon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.

AB - Purpose: To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. Results: A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. Conclusions: The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.

KW - Cancer

KW - Cryotherapy

KW - Guidelines

KW - Oral mucositis

UR - http://www.scopus.com/inward/record.url?scp=85076524237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076524237&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-05217-x

DO - 10.1007/s00520-019-05217-x

M3 - Article

C2 - 31836937

AN - SCOPUS:85076524237

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -